Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II two-cohort study of cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma with CNS metastases
2018-000759-41Phase 2Terminated
- Sponsor
- Roche
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of cobimetinib, atezolizumab and vemurafenib in melanoma (2 arms), sponsored by Roche. Primary endpoint: Intracranial objective response rate. Started Jul 2018; status: terminated.
02
Drugs
cobimetinibatezolizumabvemurafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2018-000759-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000759-41.